ELTP Stock Analysis
EL
Avoid
Based on Eyestock quantitative analysis, ELTP`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is engaged in developing and manufacturing oral, controlled-release drug products. The firm owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5 milligram tablets (mg), Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Dantrolene 25mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate, Amphetamine Sulfate Immediate Release 5mg, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Isradipine 2.5mg and 5mg capsules and Naltrexone HCl 50mg tablets.